More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...
Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases ...
2don MSN
Legal questions swirl around FDA’s new expedited drug program, including who should sign off
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
The FDA expedited drug review activity in December 2025 includes six fast-tracked therapies and the first National ...
FDA commissioner Marty Makary said it would be “magical” for consumers to see prescription drugs on pharmacy shelves instead ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
3don MSN
Exclusive - US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...
Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...
The Senate’s health committee convened its first hearing of the year on the efficacy of the chemical abortion drug ...
FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.
MedPage Today on MSN
FDA Has Taken Cautious Approach With Mifepristone, Review Suggests
Three key themes emerged across the mifepristone documents: consistent safety findings, lack of ideological bias in staff ...
An extension was required to provide time to review additional data requested by the FDA to clarify sparsentan’s clinical benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback